MedPath

Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer

Not Applicable
Recruiting
Conditions
Liver Cancer
Interventions
Registration Number
NCT05160740
Lead Sponsor
Zhujiang Hospital
Brief Summary

The of this study is to explore the clinical outcomes of indocyanine green molecular fluorescence imaging in local resection of primary hepatocellular carcinoma (CNLC Ⅰa stage).

Detailed Description

Indocyanine green molecular imaging technique is often used in the surgical treatment of primary liver cancer. Its application in hepatectomy of primary liver cancer is currently in the stage of case accumulation and clinical research. No prospective study has been conducted to determine the clinical efficacy of indocyanine green molecular imaging for local hepatectomy of primary liver cancer. On the basis of more than 1000 liver resection procedures, the investigators want to apply indocyanine green molecular imaging technology, a cheap, simple and radiation-free method, to guide surgical resection. The purpose is to assist surgical procedures and improve participants' tumor-free survival.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
348
Inclusion Criteria
  • First clinical diagnosis of primary liver cancer (China liver cancer staging, CNLC Ia stage);
  • Child-Pugh grading standard of liver function was GRADE A or B;
  • 18-66 years old;
  • Complete clinical case data;
  • limited surgical methods (local resection);
  • Voluntarily participate in the study and sign the informed consent.
Exclusion Criteria
  • There are basic diseases that cannot tolerate surgery (such as severe cardiopulmonary cerebral renal insufficiency);
  • Tumor thrombus or distant metastasis was found in main portal vein and primary branch, main hepatic vein and branch, main hepatic vein and inferior vena cava by preoperative imaging examination;
  • planned pregnancy, unplanned pregnancy and pregnancy;
  • Preoperative child-Pugh grading standard of liver function was Grade C.
  • Disease researchers that the investigator considers inappropriate to participate in this clinical trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ICG molecular fluorescence imaging guided surgeryIndocyanine green for injectionICG molecular fluorescence imaging will be used in local hepatectomy of primary liver cancer in this group
No ICG molecular fluorescence imaging guided surgeryIndocyanine green for injectionICG molecular fluorescence imaging will not be used in local hepatectomy of primary liver cancer in this group
Primary Outcome Measures
NameTimeMethod
3-year disease free survival rate36 months

No tumor recurrence within 3 years after surgery divided by total number of patients

Secondary Outcome Measures
NameTimeMethod
Intraoperative blood transfusion volume1 day

Compare intraoperative blood transfusion volume in both groups

The number of small lesions of HCC14 days

Small lesions detected by ICG fluorescence and confirmed by pathology in the intervention group

Residual tumor at the margin of liver cross-section14 days

The number of residual tumors confirmed by ICG fluorescence detection at the liver margin of the intervention group

Postoperative hospital stay30 days

Compare Postoperative hospital stay in both groups. Eg: Postoperative hospital stay is the number of days from the day of surgery to the day of discharge.

Length of the shortest cutting edge14 days

The shortest distance between tumor and resection margin was compared between the two groups by pathological diagnosis

Positive margin rate14 days

Compare positive margin rate in both groups

Negative margin rate14 days

Compare negative margin rate in both groups

Operation time1 day

Compare operation time in both groups

Intraoperative blood loss1 day

Compare intraoperative blood loss in both groups

Intraoperative biliary fistula detection rate1 day

The number of cases of successful intraoperative detection of biliary fistula by fluorescence in the intervention group divided by the total number of cases in the intervention group.

Extrahepatic metastases of primary hepatocellular carcinoma14 days

The number of extrahepatic metastases of primary liver cancer detected by ICG and confirmed by pathology in the intervention group

Postoperative liver function index 15 days

Compare the levels of Alanine aminotransferase on postoperative days 1, 3, and 5 in both groups

Postoperative liver function index 45 days

Compare the levels of total bilirubin on postoperative days 1, 3, and 5 in both groups

Prothrombin time5 days

Compare prothrombin time on postoperative days 1, 3, and 5 in both groups

Postoperative liver function index 25 days

Compare the levels of Aspartate aminotransferase on postoperative days 1, 3, and 5 in both groups

Postoperative liver function index 35 days

Compare the levels of serum albumin on postoperative days 1, 3, and 5 in both groups

Postoperative hemoglobin5 days

Compare hemoglobin on postoperative days 1, 3, and 5 in both groups

Postoperative platelets5 days

Compare platelets on postoperative days 1, 3, and 5 in both groups

Mortality rates3 months

Perioperative death was defined as death occurring within 90 days after surgery

Trial Locations

Locations (1)

Zhujiang Hospital of Southern Medical University

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath